Cargando…
Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection
The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 has resulted in more than 500 million cases and 6 million deaths. Several antiviral therapies and vaccines have been developed to mitigate the spread of this infection. However, new approaches are required to battle emerging SARS‐CoV‐2...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137278/ https://www.ncbi.nlm.nih.gov/pubmed/35633739 http://dx.doi.org/10.1002/ctd2.66 |
_version_ | 1784714344557182976 |
---|---|
author | Acharya, Arpan Kutateladze, Tatiana G. Byrareddy, Siddappa N. |
author_facet | Acharya, Arpan Kutateladze, Tatiana G. Byrareddy, Siddappa N. |
author_sort | Acharya, Arpan |
collection | PubMed |
description | The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 has resulted in more than 500 million cases and 6 million deaths. Several antiviral therapies and vaccines have been developed to mitigate the spread of this infection. However, new approaches are required to battle emerging SARS‐CoV‐2 variants containing mutations that can reduce the vaccines' efficacy. The use of a combination of antiviral drugs with inhibitors of mammalian target of rapamycin (mTOR) signalling pathways has emerged as one of the promising novel approach. In this study, we have shown that SF2523, a dual activity small molecule that inhibits PI3K and BRD4, acts synergistically with the antiviral drugs remdesivir (RDV) and MU‐UNMC‐2. Our findings suggest that the mTOR pathways are necessary for SARS‐CoV‐2 pathogenesis in human cells and that targeting PI3K/BET (bromodomain and extra‐terminal domain proteins) alone or combined with antiviral therapies is beneficial in mitigating SARS‐CoV‐2 and its variants of concern (VOCs). |
format | Online Article Text |
id | pubmed-9137278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91372782022-08-04 Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection Acharya, Arpan Kutateladze, Tatiana G. Byrareddy, Siddappa N. Clin Transl Discov Commentary The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 has resulted in more than 500 million cases and 6 million deaths. Several antiviral therapies and vaccines have been developed to mitigate the spread of this infection. However, new approaches are required to battle emerging SARS‐CoV‐2 variants containing mutations that can reduce the vaccines' efficacy. The use of a combination of antiviral drugs with inhibitors of mammalian target of rapamycin (mTOR) signalling pathways has emerged as one of the promising novel approach. In this study, we have shown that SF2523, a dual activity small molecule that inhibits PI3K and BRD4, acts synergistically with the antiviral drugs remdesivir (RDV) and MU‐UNMC‐2. Our findings suggest that the mTOR pathways are necessary for SARS‐CoV‐2 pathogenesis in human cells and that targeting PI3K/BET (bromodomain and extra‐terminal domain proteins) alone or combined with antiviral therapies is beneficial in mitigating SARS‐CoV‐2 and its variants of concern (VOCs). John Wiley and Sons Inc. 2022-05-06 2022-06 /pmc/articles/PMC9137278/ /pubmed/35633739 http://dx.doi.org/10.1002/ctd2.66 Text en © 2022 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Acharya, Arpan Kutateladze, Tatiana G. Byrareddy, Siddappa N. Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title | Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title_full | Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title_fullStr | Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title_full_unstemmed | Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title_short | Combining antiviral drugs with BET inhibitors is beneficial in combatting SARS‐CoV‐2 infection |
title_sort | combining antiviral drugs with bet inhibitors is beneficial in combatting sars‐cov‐2 infection |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137278/ https://www.ncbi.nlm.nih.gov/pubmed/35633739 http://dx.doi.org/10.1002/ctd2.66 |
work_keys_str_mv | AT acharyaarpan combiningantiviraldrugswithbetinhibitorsisbeneficialincombattingsarscov2infection AT kutateladzetatianag combiningantiviraldrugswithbetinhibitorsisbeneficialincombattingsarscov2infection AT byrareddysiddappan combiningantiviraldrugswithbetinhibitorsisbeneficialincombattingsarscov2infection |